Loading...
XTAI
4133
Market cap39mUSD
Jul 09, Last price  
20.80TWD
1D
-0.72%
1Q
-6.94%
Jan 2017
-41.70%
IPO
-81.29%
Name

Abnova Taiwan Corp

Chart & Performance

D1W1MN
XTAI:4133 chart
P/E
P/S
3.59
EPS
Div Yield, %
4.33%
Shrs. gr., 5y
-0.01%
Rev. gr., 5y
-5.10%
Revenues
351m
-1.11%
402,834,000475,072,000472,569,000463,774,000463,699,000438,112,000451,367,000439,826,000475,073,000426,023,000414,158,000456,449,000451,487,000411,756,000382,052,000355,257,000351,299,000
Net income
-1m
L
99,558,000149,045,000119,865,00076,838,00072,896,00065,643,00044,911,00053,539,00058,966,00046,118,0003,263,00036,526,00028,369,00074,843,00043,678,00061,607,000-1,141,000
CFO
-4m
L
63,721,000114,400,000134,225,00076,021,000109,778,00094,180,00073,428,00071,936,00067,529,00089,168,00074,513,000105,300,00092,875,000132,369,00076,219,00050,852,000-4,192,000
Dividend
Jun 16, 20250.9 TWD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Abnova (Taiwan) Corporation specializes in the development and distribution of a comprehensive range of recombinant proteins and antibodies. The company's extensive product portfolio caters to diverse research and diagnostic applications, featuring specialized reagents for SARS-CoV/CoV-2, nucleic acids (both DNA and RNA), and various proteins and peptides. Their offerings further include items like DNAxPab, laboratory beads, dyes, cellular lysates, microscopic slides, antibody pairs and associated kits, as well as antibody and tissue arrays. Additionally, they provide in situ hybridization products, advanced laboratory systems and automation, GMP-grade and analyte-specific reagents, and solutions for in vitro diagnostics. Beyond these product lines, Abnova supplies a broad spectrum of antibody types, such as MaxPab, monoclonal, polyclonal, recombinant, conjugate, secondary/tag, IHC/pathology, and those specifically targeting circulating rare cells. The company also delivers integrated solutions and services, encompassing gene synthesis and cytogenetic analysis, peptide services, protein expression and conjugations, custom antibody generation, and assay development. Abnova (Taiwan) Corporation operates from its headquarters in Taipei, Taiwan.
IPO date
May 27, 2008
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT